- Home
- PLRX vs INMB Comparison
PLRX vs INMB Comparison
Compare PLRX & INMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PLRX | INMB |
|---|---|---|
| Founded | 2015 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 61.1M | 64.7M |
| IPO Year | 2020 | 2018 |
Fundamental Metrics
Financial Performance| Metric | PLRX | INMB |
|---|---|---|
| Price | $0.81 | $1.13 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 6 | 2 |
| Target Price | $2.67 | ★ $7.00 |
| AVG Volume (30 Days) | ★ 344.2K | 254.7K |
| Earning Date | 11-17-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 29.97 | 11.85 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $50,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 257.14 |
| 52 Week Low | $0.83 | $1.09 |
| 52 Week High | $1.82 | $2.60 |
Technical Indicators
Market Signals| Indicator | PLRX | INMB |
|---|---|---|
| Relative Strength Index (RSI) | 31.54 | 24.75 |
| Support Level | N/A | N/A |
| Resistance Level | $0.90 | $1.52 |
| Average True Range (ATR) | 0.04 | 0.12 |
| MACD | 0.00 | -0.02 |
| Stochastic Oscillator | 9.73 | 10.76 |
Price Performance
Historical ComparisonAbout PLRX Pliant Therapeutics Inc.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of integrin-based therapies. The company operates as a single reportable segment focused on developing and commercializing novel integrin-based treatments. Its lead product candidate, PLN-101095, is an oral small molecule targeting integrins for the treatment of solid tumors. The company also advances a pipeline of integrin-based programs across multiple disease areas through its proprietary drug discovery platform.
About INMB INmune Bio Inc.
INmune Bio Inc is a clinical stage biotechnology pharmaceutical company focused on developing and commercializing its product candidates to treat diseases where inflammation and immunology cause a dysfunctional immune system contributing to disease. The company's pipeline products include INKmune, XPro1595, and others. It has three product platforms; The CORDStrom product platform, The DN-TNF product platform, and The Natural Killer Cell Priming Platform.